This meta-analysis showed that all patients experienced AEs and the most common AEs in ATC with lenvatinib were hypertension, proteinuria, fatigue, and asthenia, which are related toxic side effects of VEGF-targeted therapy (37). This evidence concerns the gene VEGFA and asthenia.